ITNS (Itonis) EBITDA Margin %: 0.00% (As of Feb. 2008)


What is Itonis EBITDA Margin %?

Itonis ITNS EBITDA Margin % is 0.00% as of Feb. 2008.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Itonis's EBITDA for the three months ended in Feb. 2008 was $-0.42 Mil. Itonis's Revenue for the three months ended in Feb. 2008 was $0.00 Mil. Therefore, Itonis's EBITDA margin for the quarter that ended in Feb. 2008 was 0.00%.

Itonis  (OTCPK:ITNS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Itonis EBITDA Margin % Related Terms

Itonis EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Itonis's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Itonis EBITDA Margin % Chart

Itonis Annual Data
Trend Nov05 Nov06 Nov07
EBITDA Margin %
0.00 -9,650.00 -623.19

Itonis Quarterly Data
Nov05 Feb06 May06 Aug06 Nov06 Feb07 May07 Aug07 Nov07 Feb08
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only -110.00 -2,866.67 -910.71 -7,342.86 0.00

ITNS vs FZMD, SNYR, SGMFF: EBITDA Margin % Comparison

For the Medical Distribution subindustry, Itonis's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Itonis EBITDA Margin % vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Itonis's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Itonis's EBITDA Margin % falls into.


Itonis EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Itonis's EBITDA Margin % for the fiscal year that ended in Nov. 2007 is calculated as

EBITDA Margin %=EBITDA (A: Nov. 2007 )/Revenue (A: Nov. 2007 )
=-1.29/0.207
=-623.19 %

Itonis's EBITDA Margin % for the quarter that ended in Feb. 2008 is calculated as

EBITDA Margin %=EBITDA (Q: Feb. 2008 )/Revenue (Q: Feb. 2008 )
=-0.415/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Itonis (ITNS) has a EBITDA Margin % of 0.00% as of Feb. 2008. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Itonis and its competitors.
Is Itonis' EBITDA Margin % too high?
Itonis' current EBITDA Margin % is 0.00%.
How does Itonis' EBITDA Margin % compare to FZMD and SNYR?
Itonis' EBITDA Margin % of 0.00% can be compared against companies in the Medical Distribution industry. The industry median EBITDA Margin % is 4.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Itonis and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Itonis's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Itonis stock overvalued right now?
Itonis (ITNS) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Itonis (ITNS), the current EBITDA Margin % is 0.00% as of Feb. 2008. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Itonis Business Description

Address 25422 Trabuco Road, Suite 105-297, Lake Forest, CA, USA, 92630
Itonis Inc is a development-stage company. It operates as a holding company, which engages in the development and distribution of products to the medical and pharmaceutical industry. It is presently focused on marketing its Emesyl homeopathic anti-nausea product for retail sale. It produces and markets over-the-counter and prescription homeopathic preparations to treat both common ailments and chronic diseases.